Richard Law
Stock Analyst at Goldman Sachs
(2.57)
# 1,557
Out of 5,182 analysts
80
Total ratings
28.95%
Success rate
1.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Buy | $36 → $31 | $17.53 | +76.84% | 6 | Apr 7, 2026 | |
| BCAX Bicara Therapeutics | Maintains: Neutral | $14 → $16 | $23.78 | -32.72% | 1 | Mar 31, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $38 → $27 | $15.19 | +77.75% | 8 | Mar 18, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Neutral | $65 → $95 | $103.97 | -8.63% | 1 | Mar 3, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintains: Sell | $2 → $3 | $3.86 | -22.28% | 4 | Mar 2, 2026 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $30 → $34 | $34.39 | -1.13% | 4 | Mar 2, 2026 | |
| MLTX MoonLake Immunotherapeutics | Downgrades: Sell | $8 → $10 | $17.70 | -43.50% | 5 | Jan 15, 2026 | |
| RCUS Arcus Biosciences | Upgrades: Buy | $16 → $28 | $26.00 | +7.69% | 1 | Jan 13, 2026 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $67 | $41.71 | +60.63% | 2 | Jan 12, 2026 | |
| NUVL Nuvalent | Maintains: Buy | $120 → $135 | $104.17 | +29.60% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $29 | $24.17 | +19.98% | 2 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $52 | $30.12 | +72.64% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $4 → $3 | $7.36 | -59.24% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $30 | $32.28 | -7.06% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $20.39 | -46.05% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $32.34 | +45.33% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $55.08 | +14.38% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $86.26 | -57.11% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $13.85 | +448.74% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $3.18 | +340.94% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $10.26 | +494.54% | 4 | May 8, 2023 |
Viridian Therapeutics
Apr 7, 2026
Maintains: Buy
Price Target: $36 → $31
Current: $17.53
Upside: +76.84%
Bicara Therapeutics
Mar 31, 2026
Maintains: Neutral
Price Target: $14 → $16
Current: $23.78
Upside: -32.72%
Olema Pharmaceuticals
Mar 18, 2026
Maintains: Buy
Price Target: $38 → $27
Current: $15.19
Upside: +77.75%
Protagonist Therapeutics
Mar 3, 2026
Maintains: Neutral
Price Target: $65 → $95
Current: $103.97
Upside: -8.63%
Rocket Pharmaceuticals
Mar 2, 2026
Maintains: Sell
Price Target: $2 → $3
Current: $3.86
Upside: -22.28%
Celldex Therapeutics
Mar 2, 2026
Maintains: Neutral
Price Target: $30 → $34
Current: $34.39
Upside: -1.13%
MoonLake Immunotherapeutics
Jan 15, 2026
Downgrades: Sell
Price Target: $8 → $10
Current: $17.70
Upside: -43.50%
Arcus Biosciences
Jan 13, 2026
Upgrades: Buy
Price Target: $16 → $28
Current: $26.00
Upside: +7.69%
Crinetics Pharmaceuticals
Jan 12, 2026
Upgrades: Buy
Price Target: $67
Current: $41.71
Upside: +60.63%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $104.17
Upside: +29.60%
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $24.17
Upside: +19.98%
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $30.12
Upside: +72.64%
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $7.36
Upside: -59.24%
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $32.28
Upside: -7.06%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $20.39
Upside: -46.05%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $32.34
Upside: +45.33%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $55.08
Upside: +14.38%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $86.26
Upside: -57.11%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $13.85
Upside: +448.74%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $3.18
Upside: +340.94%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $10.26
Upside: +494.54%